You are here

ENHANCED LOCAL LYMPH NODE ASSAY USING FLOW CYTOMETRY

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44ES010234-02
Agency Tracking Number: ES010234
Amount: $1,142,638.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
MB RESEARCH LABORATORIES, INC. BOX 178, 1756 WENTZ RD
SPINNERSTOWN, PA 18968
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 GEORGE DEGEORGE
 (215) 536-4110
 INFO@MBRESEARCH.COM
Business Contact
 GEORGE DEGEORGE
Phone: (215) 536-4110
Email: INFO@MBRESEARCH.COM
Research Institution
N/A
Abstract

DESCRIPTION (Applicant?s abstract): Although the murine Local Lymph Node Assay
(LLNA) is effective at detecting potential irritants/sensitizers, this assay,
in its current standard form: 1) cannot readily differentiate some types of
irritants from respiratory and contact sensitizers; 2) utilizes moderate
amounts of radioactive material and; 3) requires increased numbers of animals
to determine the different endpoints (i.e., proliferation, immunophenotype) to
fully characterize the response of an animal to a topically-applied chemical.
To enhance and improve this important test, our company has implemented several
innovative modifications to the standard LLNA. We have applied flow cytometric
techniques to this assay to increase the sensitivity/specificity of the assay,
eliminate the use of radioactive material and decrease the number of animals
used for screening. It has been determined by the results of SBIR Phase I
studies that the proposed enhanced flow cytometry-based LLNA is technically and
commercially feasible. However, to develop this assay to its full commercial
potential, which our company would provide to the chemical, pharmaceutical and
consumer products industries, our group must: 1) validate the enhanced version
of the LLNA; 2) establish the cytometry-based LLNA as a GLP compliant assay at
our company and; 3) develop and provide various versions of the enhanced LLNA
for our clients.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government